NOVATO, Calif., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company, today announced that Shalini Sharp, the company's Chief Financial Officer, will present at the Wedbush 2013 Life Sciences Management Access Conference in New York, NY on August 13, 2013 at 3:05pm E.T. and at the Canaccord Genuity Annual Growth Conference in Boston, MA on August 14, 2013 at 3:30pm E.T. Ms. Sharp will provide a corporate overview and update at both conferences and will be available to conduct one-on-one meetings with investors.
Ultragenyx is a privately held, clinical-stage biotechnology company committed to bringing to market life-transforming therapeutics for patients with rare and ultra-rare metabolic genetic diseases. Founded in 2010, the company is rapidly building a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no effective treatments.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.
CONTACT: Ultragenyx Pharmaceutical Inc. 415-483-8800 For Media, Bee Nguyen For Investors, Shalini SharpSource:Ultragenyx Pharmaceutical Inc.